Cutting-Edge Nanocarrier-Based Strategies in the Management of Leukaemia

Dr. Devesh U. Kapoor is Professor of Pharmaceutics at Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, affiliated with Gujarat Technological University. His academic and research expertise centers on pharmaceutics, nanodrug delivery, and modified‑release drug delivery systems. Dr. Kapoor has made extensive scholarly contributions through research and review publications, book chapters, and edited volumes with international publishers. He is actively involved in postgraduate and doctoral research supervision in advanced drug delivery technologies. His editorial experience includes serving in senior editorial roles for international journals across pharmacology, pharmaceutics, and biomedical sciences, along with regular peer‑review activity for a wide range of scientific journals. Dr. Kapoor has also secured competitive research and academic development funding and is a frequent invited speaker at national scientific meetings, workshops, and academic programs. Dr. Bhupendra Gopalbhai Prajapati is Professor (Research Cadre) at Parul Institute of Pharmacy, Parul University, Gujarat, India, and serves as Adjunct Professor in the Department of Industrial Pharmacy at Silpakorn University, Thailand. His academic, research, and industry expertise focuses on lipid‑based formulations, nano‑ and microparticulate drug delivery systems, and strategies to enhance drug bioavailability. Dr. Prajapati has received several academic and professional honors recognizing excellence in teaching and research. He has made substantial scholarly contributions through research and review publications, book chapters, and edited volumes in pharmaceutical sciences. Actively engaged in postgraduate and doctoral mentoring, he supports research training in advanced drug delivery and formulation science. Dr. Prajapati also serves in editorial and section‑editor roles for international scientific publications, contributing to the advancement and quality of pharmaceutical research dissemination. Dr. Anand Krishnan, Principal Investigator in Chemical Pathology, Office of the Dean, Faculty of Health Sciences, University of the Free State, South Africa. He leads the Precision Medicine Integrative Nano Diagnostics (P-MIND) laboratories, which focus on the biological functions of extracellular vesicles (EVs) in synthetic biology. His research encompasses cell surface protein modification, biomarker discovery through EVs derived from liquid biopsies, and the role of circulating biomarkers in disease development and stem cell biology. Dr. Krishnan has authored over 150 articles and edited eight books published by Elsevier, Springer, and Wiley. He received the National Research Foundation (NRF) rating for Next Generation Researchers in South Africa. In the latest list published by Stanford University, Dr. Krishnan was named among the Top 2% of the most influential scientists worldwide. He is an active member of the International Society of Extracellular Vesicles (ISEV), the African Organisation for Research and Training in Cancer (AORTIC), and the American Association of Cancer Research (AACR). Recently, he has been serving as an editor for the eLife journal, focusing on the Africa region.

• 1. Introduction2. siRNA and miRNA therapies for leukaemia3. Gene therapy for leukaemia4. Exploring Polymeric nanoparticles in leukaemia management5. Magnetic Nanoparticles in Leukemia Therapy: Advancements and Future Directions6. Mesoporous Silica Nanoparticles: A Novel Approach in Targeted Leukemia Therapy7. Targeted Leukemia Therapy with Solid Lipid Nanoparticles: Potential and Progress8. The Role of Exosomes in Leukemia Treatment: Advancements in Biomarker Discovery and Drug Delivery9. Nanoemulsion-Based Drug Delivery in Leukemia: Potential and Progress in Therapeutic Applications10. Advances in Leukemia Treatment using Micelles and Dendrimers11. Revolutionizing Leukemia Therapy with Liposomes and Niosomes: Targeted Delivery and Improved Efficacy12. Biological and immunological aspects of nanocarriers and nano-vaccines13. Leveraging AI and machine learning for prostate cancer management 14. Role of DNA Origami and mRNA/siRNA nanocarriers in prostate cancer